Privia Health Group Inc’s filing revealed that its Chief Executive Officer Mehrotra Parth unloaded Company’s shares for reported $0.39 million on May 13 ’25. In the deal valued at $24.52 per share,15,909 shares were sold. As a result of this transaction, Mehrotra Parth now holds 407,234 shares worth roughly $10.18 million.
Then, Mehrotra Parth sold 13,773 shares, generating $344,187 in total proceeds. Upon selling the shares at $24.99, the Chief Executive Officer now owns 423,143 shares.
Before that, Mountcastle David sold 3,322 shares. Privia Health Group Inc shares valued at $83,017 were divested by the EVP & Chief Financial Officer at a price of $24.99 per share. As a result of the transaction, Mountcastle David now holds 172,909 shares, worth roughly $4.32 million.
Needham initiated its Privia Health Group Inc [PRVA] rating to a Buy in a research note published on January 10, 2025; the price target was $25. A number of analysts have revised their coverage, including Macquarie’s analysts, who began to cover the stock in mid December with a ‘”an Outperform”‘ rating. KeyBanc Capital Markets began covering PRVA with “an Overweight” recommendation on October 11, 2024. Robert W. Baird started covering the stock on May 30, 2024. It rated PRVA as “an Outperform”.
Price Performance Review of PRVA
On Monday, Privia Health Group Inc [NASDAQ:PRVA] saw its stock fall -0.08% to $25.00. Over the last five days, the stock has lost -0.24%. Privia Health Group Inc shares have risen nearly 27.88% since the year began. Nevertheless, the stocks have risen 43.93% over the past one year.
How much short interest is there in Privia Health Group Inc?
A steep rise in short interest was recorded in Privia Health Group Inc stocks on 2025-04-30, dropping by -0.81 million shares to a total of 3.35 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 4.17 million shares. There was a decline of -24.3%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 22, 2024 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $25 price target.
